| |
AATD + AUGa
|
AATD-AUGb
|
AATD PFTnormc
|
non-AATD COPDd
|
Healthye
|
|---|
|
FVC (liters)
|
3.85 ± 0.42
|
2.88 ± 0.16c
|
4.27 ± 0.64e
|
2.80 ± 0.32c,e
|
3.96 ± 0.57d
|
|
FVC (% pred)
|
88 ± 6c
|
79 ± 5c
|
109 ± 6e
|
77 ± 8c,e
|
95 ± 6d
|
|
FEV1 (liters)
|
1.23 ± 0.25c,e
|
1.35 ± 0.22c,e
|
3.22 ± 0.47e
|
1.49 ± 0.11c,e
|
3.07 ± 0.35d
|
|
FEV1 (% pred)
|
35 ± 5c,e
|
47 ± 7c,e
|
107 ± 4e
|
54 ± 7c,e
|
93 ± 4d
|
|
FEV1/FVC
|
31 ± 3c,d,e
|
47 ± 7c,e
|
76 ± 7c,e
|
56 ± 4c,e
|
79 ± 2d
|
|
FEV1/FVC (% pred)
|
40 ± 4c,d,e
|
61 ± 10c,e
|
97 ± 2e
|
71 ± 6c,e
|
99 ± 3d
|
|
Bike (two-legs) exercise
| | | | | |
|
Watts
|
62 ± 6c,e
|
46 ± 11c,e
|
176 ± 47d,e
|
70 ± 11c,e
|
126 ± 17d
|
|
VO2peak (L/min)
|
1.02 ± 0.11c,e
|
0.69 ± 0.13c,e
|
2.07 ± 0.51d
|
1.16 ± 0.12c,e
|
1.71 ± 0.25d
|
|
VO2peak (ml/kg/min)
|
12.6 ± 0.5c
|
9.5 ± 1.1c,e
|
26.9 ± 5.6d,e
|
14.9 ± 1.7c
|
20.3 ± 3.3
|
|
Knee extensor (single-leg) exercise
| | | | | |
|
Watts
|
25 ± 3c
|
21 ± 7c
|
59 ± 23d,e
|
21 ± 3c
|
26 ± 1
|
|
Smoking history
| | | | | |
|
Never
|
17%
|
0%
|
25%
|
0%
|
0%
|
|
Ex-smoker
|
83%
|
100%
|
75%
|
43%
|
100%
|
|
Current
|
0%
|
0%
|
0%
|
57%
|
0%
|
- Data are mean ± SE. AATD, alpha-1 antitrypsin deficient; AUG, augmentation therapy; PFTnorm, pulmonary function testing normal; AAT, alpha-1 antitrypsin; COPD, chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV1, forced expiratory volume at 1 sec; VO2peak, peak oxygen consumption during exercise. Significance difference between group is denoted as follows, ‘c’ different compared to AATD PFTnorm,‘d’ different compared to COPD, ‘e’ different compared to Healthy. No differences with respect to AATD + AUG ‘a’ or AATD-AUG ‘b’ were found. In all cases, significance is p ≤ 0.05.
